W2P... Thanks for the good article/update. I have a question for you (and the board).
The article states "The company has partnered with the H. Lee Moffitt Cancer & Research Institute at the University of South Florida for nine projects"
I show only 7 projects on my DNAG Products Pipeline list...3 originated by DNAG (now working with Moffitt), and 4 projects specifically started with Moffitt:
1) Ovanome - Taxol/Carboplatin efficacy
* R/D 1998…Announce Mar 2000…Validation Studies 2002-2004…Clinical Study May 2005…FDA late 2006?….
2) Statinome - Lipitor, Zocor, efficacy, liver, muscle adverse myalgia response
* R/D 1998….Clinical Studies late 2004/early 2005…FDA 2007?...Market?...
3) Acenome - Enalapril, Lisinopril efficacy, muscle, adverse cough
* R/D 1998….Clinical Studies late 2004/early 2005…FDA 2007?...Market?...
4) BC-LOH – Breast Cancer (DNAP/Moffitt)
* R/D 2003…………………Clinical Studies 2005/2006…..FDA 2007-8?...Market?
5) Ondansetron – Chemo-nausea (DNAP/Moffitt)
* R/D 2003…………………Clinical Studies 2005/2006…..FDA 2007-8?...Market?
6) Melphalan/Topotecan – Multiple Myeloma (DNAP/Moffitt)
* R/D 2003…………………Clinical Studies 2005/2006…..FDA 2007-8?...Market?
7) Xeliri/Xelox – Colon Cancer (DNAP/Moffitt)
* R/D 2003…………………Clinical Studies 2005/2006…..FDA 2007-8?...Market?
Question: Does anyone have information on the other DNAG/Moffitt projects (links, references, PR's)...?
I really like the sound of 9 ongoing cancer/drug projects at Moffitt. I'd like it better if I knew what they were...lol!
I was getting ready to update the DNAG Products Pipeline list to include our 3 new drugs from Biofrontera and would like to add the new Moffitt projects as well.
In any case, more drug projects boiling on the stove means more future opportunities for DNAG and investors for sure...!
God Bless and take care,
Robert
